[The early management of the sepsis: use of a guidelines document in hospital. Experience at "Carlo Poma" Hospital in Mantova]. / La gestione precoce della sepsi: utilizzo di linee-guida ospedaliere. Esperienza dell'Azienda Ospedaliera "Carlo Poma" di Mantova.

Today the sepsis represents a very important clinical entity. The Surviving Sepsis Campaign assessed an incidence of sepsis equal to 3 cases/1,000 inhabitants. In UK more than 30,000 cases of severe sepsis are calculated; furthermore the patients with sepsis are increasing worldwide (near 18 millions of cases per year). Because of its high mortality, the sepsis represents one of the main causes of death in the world, also in the developing countries where it causes near sixty percent of the total deaths yearly. The early diagnosis and therapy are very important elements for the outcome of the patients. The Authors present the results of the adoption in their hospital of a guidelines document for the management of the septic patient, that show a decrease of their mortality due to the early diagnosis and specific treatments.

[Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy]. / Utilizzo clinico di plasma virus-inattivato. Esperienza del Servizio Trasfusionale di Mantova.

BACKGROUND: Fresh Frozen Plasma (FFP) is a blood component whose clinical use is widespread worldwide. Transfusion safety of this product is ensured by legally obligatory tests. Although these tests are carried out on each plasma donation, safety levels can be further improved by using some technical procedures, such as, among others, methylene blue (MB) and solvent-detergent (SD) viral inactivation methods. The DMTE (Blood Transfusion Unit) in Mantova has used the pharmaceutical-like SD virally inactivated plasma since 2007 (Plasmasafe, Kedrion) as replacement of the PFC by each single donor. Guidelines for the usage of both products are the same. MATERIALS AND METHODS: With the main aim of assessing the therapeutic effectiveness and safety of Plasmasafe, we decided to clinically monitor transfusions performed with this product on patients of the Intensive Care Unit at the city hospital in Mantova. In addition, we controlled some coagulation parameters (PT, aPTT, ATIII, Fibrinogen, PC, PS, FV, FVII, FVIII) before and 24 hours after the Plasmasafe infusion. RESULTS: From a clinical point of view, the use of Plasmasafe always led to a significant reduction, or complete stop, of the bleeding. No transfusion-related adverse events were recorded. As regards, the most relevant laboratory results, a marked increase in the above mentioned hemostatic parameters was detected. Furthermore, patients transfused with this product received a mean volume significantly lower than an historical cohort of patients treated with FFP (503 mL with Plasmasafe versus 1549 mL with FFP, P<0.001). CONCLUSIONS: The results of our study clearly document that Plasmasafe, a virally inactivated pharmaceutical-like product with a standardized content of coagulation factors, is a safe and cost-effective treatment, able to rapidly correct hemostatic abnormalities, for critical patients.